1. Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727–38.
2. Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2(16001):1–20.
3. Gesualdo L, Griffin S, Tharaux PL. The dual role of endothelin-1 and angiotensin II in disease progression of focal segmental glomerulosclerosis and IgA nephropathy. EMJ Nephrol. 2022;10(1):20–9.
4. Szklarzewicz J. The humanistic burden of rare kidney diseases, understanding the impact of focal segmental glomerulosclerosis and IgA nephropathy on patients and caregivers study (HONUS): preliminary results for IgA nephropathy in the United States [abstract no. SA-PO699 plus poster]. J Am Soc Nephrol. 2022;33(Suppl.):795.
5. Jhaveri KD, Bensink ME, Bunke M, et al. Humanistic and economic burden of IgA nephropathy: systematic literature reviews and narrative synthesis. Pharmacoecon Open. 2023;7(5):709–22.